Bengt JÃ¶nsson

List of Publications by Year
in descending order

95 papers	5,820 citations	117625 34 h-index	74163 75 g-index
99 all docs	99 docs citations	99 times ranked	7450 citing authors

#	Article	IF	Citations
1	Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?. Value in Health, 2004, 7, 518-528.	0.3	647
2	Cost-Effectiveness Analysis Alongside Clinical Trials IIâ€"An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.3	539
3	Osteoporosis: burden, health care provision and opportunities in the EU. Archives of Osteoporosis, 2011, 6, 59-155.	2.4	459
4	Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care, 2008, 24, 244-258.	0.5	356
5	Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporosis International, 2006, 17, 637-650.	3.1	272
6	Excess mortality after hospitalisation for vertebral fracture. Osteoporosis International, 2004, 15, 108-112.	3.1	250
7	What Price Depression?. British Journal of Psychiatry, 1994, 164, 665-673.	2.8	216
8	Ten arguments for a societal perspective in the economic evaluation of medical innovations. European Journal of Health Economics, 2009, 10, 357-359.	2.8	196
9	Health related quality of life in different states of breast cancer. Quality of Life Research, 2007, 16, 1073-1081.	3.1	183
10	The cost of cancer in Europe 2018. European Journal of Cancer, 2020, 129, 41-49.	2.8	182
11	Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis and Rheumatism, 1999, 42, 347-356.	6.7	159
12	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	148
13	EBM, HTA, and CER: Clearing the Confusion. Milbank Quarterly, 2010, 88, 256-276.	4.4	140
14	The societal burden of osteoporosis in Sweden. Bone, 2007, 40, 1602-1609.	2.9	110
15	Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporosis International, 2011, 22, 967-982.	3.1	106
16	The cost and burden of cancer in the European Union 1995â€"2014. European Journal of Cancer, 2016, 66, 162-170.	2.8	99
17	The cost of a hip fracture: Estimates for 1,709 patients in Sweden. Acta Orthopaedica, 1997, 68, 13-17.	1.4	98
18	Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Monthly Notices of the Royal Astronomical Society: Letters, 2008, 79, 269-280.	3.3	90

#	Article	IF	Citations
19	Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. European Journal of Health Economics, 2019, 20, 427-438.	2.8	85
20	Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 239-249.	2.2	72
21	Changing health environment: The challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics, 2004, 22, 5-10.	3.3	70
22	Costs of Mini Mental State Examination-Related Cognitive Impairment. Pharmacoeconomics, 1999, 16, 409-416.	3.3	65
23	The Economic Cost of Multiple Sclerosis in Sweden in 1994. Pharmacoeconomics, 1998, 13, 597-606.	3.3	62
24	Cost of breast cancer in Sweden in 2002. European Journal of Health Economics, 2007, 8, 5-15.	2.8	61
25	Economic Evaluation of Pharmaceuticals. Pharmacoeconomics, 1993, 4, 173-186.	3.3	58
26	Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation. Value in Health, 2014, 17, 707-713.	0.3	55
27	Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. European Journal of Health Economics, 2011, 12, 263-271.	2.8	54
28	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Reports, 2020, 2, 100142.	4.9	53
29	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. International Journal of Technology Assessment in Health Care, 2010, 26, 71-78.	0.5	52
30	Impact of Inhaled Corticosteroids on Acute Asthma Hospitalization in Sweden. Medical Care, 1996, 34, 1188-1198.	2.4	51
31	Cost-effectiveness of Misoprostol in Sweden. International Journal of Technology Assessment in Health Care, 1992, 8, 234-244.	0.5	46
32	Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2151-2165.	2.2	44
33	A Review of Cost-Effectiveness Analyses of Hypertension Treatment. Pharmacoeconomics, 1992, 1, 250-264.	3.3	40
34	The End of the International Reference Pricing System?. Applied Health Economics and Health Policy, 2016, 14, 1-8.	2.1	37
35	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Quality of Life Research, 2018, 27, 707-716.	3.1	36
36	Economic Evaluation Alongside Multinational Clinical Trials:Study Considerations for GUSTO iib. International Journal of Technology Assessment in Health Care, 1997, 13, 49-58.	0.5	33

#	Article	IF	Citations
37	Towards a cancer mission in Horizon Europe: recommendations. Molecular Oncology, 2020, 14, 1589-1615.	4.6	33
38	A COMPUTER MODEL TO ANALYZE THE COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY. International Journal of Technology Assessment in Health Care, 1999, 15, 352-365.	0.5	32
39	Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden. Pharmacoeconomics, 2001, 19, 901-916.	3.3	30
40	CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?. International Journal of Technology Assessment in Health Care, 2012, 28, 159-165.	0.5	30
41	Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of stockholmâ€”a stochastic model of exercise and dietary advice. Preventive Medicine, 2003, 36, 403-409.	3.4	29
42	Pricing and Reimbursement of Pharmaceuticals in Sweden. Pharmacoeconomics, 1994, 6, 51-60.	3.3	28
43	Technology Assessment for New Oncology Drugs. Clinical Cancer Research, 2013, 19, 6-11.	7.0	27
44	The Cost Effectiveness of Helicobacter pylori Eradication versus Maintenance and Episodic Treatment in Duodenal Ulcer Patients in Sweden. Pharmacoeconomics, 1995, 8, 410-427.	3.3	24
45	An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respiratory Medicine, 2004, 98, 1146-1154.	2.9	24
46	Economic Evaluation of Drug Therapy. Pharmacoeconomics, 1992, 1, 325-337.	3.3	20
47	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis, 2010, 5, 19-48.	2.4	18
48	Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases. Medical Care, 2012, 50, 1076-1085.	2.4	18
49	Bringing in health technology assessment and costâ€effectiveness considerations at an early stage of drug development. Molecular Oncology, 2015, 9, 1025-1033.	4.6	18
50	Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. Journal of Hypertension, 2005, 23, 1425-1431.	0.5	16
51	Relative effectiveness and the European pharmaceutical market. European Journal of Health Economics, 2011, 12, 97-102.	2.8	16
52	Principles for planning and conducting comparative effectiveness research. Journal of Comparative Effectiveness Research, 2012, 1, 431-440.	1.4	16
53	IQWiG: an opportunity lost?. European Journal of Health Economics, 2008, 9, 205-207.	2.8	15
54	Cost-Effectiveness of Antihypertensive Treatment. Pharmacoeconomics, 1993, 3, 36-44.	3.3	14

#	Article	IF	Citations
55	Cancer vaccines and immunotherapeutics. Human Vaccines and Immunotherapeutics, 2012, 8, 1360-1363.	3.3	14
56	Drug Expenditure and New Drug Introductions. Pharmacoeconomics, 1993, 4, 215-225.	3.3	12
57	Costâ€effectiveness: a new criterion for selecting therapy. Journal of Internal Medicine, 1995, 237, 1-3.	6.0	10
58	Disruptive innovation and EU health policy. European Journal of Health Economics, 2017, 18, 269-272.	2.8	10
59	Cost effectiveness in practice and its effect on clinical outcomes. Journal of Cancer Policy, 2014, 2, 12-21.	1.4	9
60	Missionâ€oriented translational cancer research â€“ health economics. Molecular Oncology, 2019, 13, 636-647.	4.6	9
61	Propelling Health Care into the Twenties. Biomedicine Hub, 2020, 5, 1-53.	1.2	9
62	Economic evaluation and clinical uncertainty: Response to freemantle and maynard. Health Economics (United Kingdom), 1994, 3, 305-307.	1.7	8
63	Time for a common standard for cost-effectiveness in Europe?. European Journal of Health Economics, 2006, 7, 223-224.	2.8	8
64	Patient access to rheumatoid arthritis treatments. European Journal of Health Economics, 2008, 8, 35-38.	2.8	8
65	Cost-Effectiveness of Omeprazole and Ranitidine in the Treatment of Duodenal Ulcer. Pharmacoeconomics, 1994, 5, 44-55.	3.3	7
66	The Porto European Cancer Research Summit 2021. Molecular Oncology, 2021, 15, 2507-2543.	4.6	7
67	The burden and direct cost of cancer in Europe (EU-28).. Journal of Clinical Oncology, 2016, 34, 6618-6618.	1.6	7
68	UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. International Journal of Technology Assessment in Health Care, 2015, 31, 363-370.	0.5	6
69	Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study. BMC Psychiatry, 2018, 18, 80.	2.6	6
70	Cost of Cancer: Healthcare Expenditures and Economic Impact. Recent Results in Cancer Research, 2019, 213, 7-23.	1.8	6
71	Costs of Dementia: A Review. , 2002, , 335-381.		5
72	Economic evaluation for pharmaceuticals in Germany. European Journal of Health Economics, 2007, 8, 1-2.	2.8	5

#	Article	IF	Citations
73	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. International Journal of Technology Assessment in Health Care, 2017, 33, 609-619.	0.5	5
74	Health technology assessment: Regulators or payersâ€"Who will take the lead?. Clinical Therapeutics, 2008, 30, 960-963.	2.5	4
75	Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporosis International, 2012, 23, 2063-2065.	3.1	4
76	Efficiency and productivity of cancer care in Europe. Journal of Cancer Policy, 2019, 21, 100194.	1.4	4
77	A comparative study on costs of cancer and access to medicines in Europe.. Journal of Clinical Oncology, 2020, 38, e19051-e19051.	1.6	4
78	Being NICE is not the problem!. European Journal of Cancer, 2009, 45, 1100-1102.	2.8	3
79	Costs of Dementia: A Review. , 2003, , 341-387.		2
80	Evaluating HTA principles. International Journal of Technology Assessment in Health Care, 2010, 26, 429-430.	0.5	2
81	RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH. International Journal of Technology Assessment in Health Care, 2015, 31, 371-379.	0.5	2
82	Assessment of value for resource allocation in cancer care. Journal of Cancer Policy, 2017, 11, 12-18.	1.4	2
83	Value appropriation in hepatitis C. European Journal of Health Economics, 2021, , 1.	2.8	2
84	The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer. Chinese Clinical Oncology, 2014, 3, 23.	1.2	2
85	Cost-effectiveness of new drugs: A systematic review of published evidence for new chemical entity drugs introduced on the Swedish market 1987â€"2000. International Journal of Technology Assessment in Health Care, 2005, 21, 187-193.	0.5	1
86	Outcome measurement in economic evaluation. Health Economics (United Kingdom), 1996, 5, 279-296.	1.7	1
87	The value of tamoxifen and trastuzumab in breast cancer treatment: A study based on uptake and use in Sweden.. Journal of Clinical Oncology, 2014, 32, 589-589.	1.6	1
88	Access to cancer drugs in Europe years 2005-2014.. Journal of Clinical Oncology, 2016, 34, e18015-e18015.	1.6	1
89	Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status.. Journal of Clinical Oncology, 2017, 35, 6535-6535.	1.6	1
90	Commentary. European Journal of Health Economics, 2002, 3, 139-139.	2.8	0

#	Article	IF	Citations
91	A review of European studies on the economic burden of brain diseases. European Journal of Health Economics, 2004, 5, s4-s4.	2.8	0
92	A 3-year lifestyle intervention for adults at moderate to high risk of cardiovascular disease is cost effective when added to standard care and improves physical health-related quality of life. Evidence-Based Medicine, 2011, 16, 70-71.	0.6	0
93	Drug utilization research in the area of cancer drugs. , 2016, , 315-327.		0
94	The Three-Way Pendulum of Healthcare Innovation. Biomedicine Hub, 2017, 2, 1-4.	1.2	0
95	Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?. Journal of Clinical Oncology, 2016, 34, 6620-6620.	1.6	0